A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Crohn's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 29 May 2019 Planned End Date changed from 29 Apr 2020 to 6 Aug 2020.
- 29 May 2019 Planned primary completion date changed from 7 Jan 2020 to 9 Apr 2020.
- 29 May 2019 Status changed from recruiting to active, no longer recruiting.